|
1
|
Yang H, Zhang X, Lu Y, Wang X, Zhang Z, Xu H, Li F, Chen Q, Bai Y, Bai X, Zhang L, Liu L. Ailanthone induces autophagy and ferroptosis in non‑small cell lung cancer Lewis cells. Mol Clin Oncol 2024; 20:25. [PMID: 38410186 PMCID: PMC10895402 DOI: 10.3892/mco.2024.2723] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2023] [Accepted: 01/17/2024] [Indexed: 02/28/2024] Open
Abstract
Ailanthone (AIL), a monomer derived from ailanthus in Chinese medicine, has been demonstrated to have antitumor effects, albeit the underlying mechanism is unknown. Autophagy and ferroptosis are two modes of cell death that have been championed as potential mechanisms implicated in the antitumor effects of various drugs. The present study demonstrated that AIL effectively suppresses the Lewis cell proliferation in non-small cell lung cancer using MTT and colony formation assays. Autophagy and ferroptosis were verified using western blotting, immunofluorescence and ferroptosis detection. Additionally, the findings revealed that regulating the AMPK/mTOR/p70S6k signaling pathway may be the underlying mechanism for the antitumor effect of AIL. The present study established a theoretical foundation for further research into the utilization of AIL as a novel antitumor approach.
Collapse
Affiliation(s)
- Hongbin Yang
- Department of Immunology, The Affiliated Hospital of Chengde Medical University, Chengde, Hebei 067000, P.R. China
| | - Xiaotong Zhang
- Department of Immunology, The Affiliated Hospital of Chengde Medical University, Chengde, Hebei 067000, P.R. China
| | - Yanjie Lu
- Department of Pathology Chengde Medical University, The Affiliated Hospital of Chengde Medical University, Chengde, Hebei 067000, P.R. China
| | - Xin Wang
- Department of Oncology, The Affiliated Hospital of Chengde Medical University, Chengde, Hebei 067000, P.R. China
| | - Zhengxin Zhang
- Department of Pathology Chengde Medical University, The Affiliated Hospital of Chengde Medical University, Chengde, Hebei 067000, P.R. China
| | - Hailan Xu
- Department of Oncology, The Affiliated Hospital of Chengde Medical University, Chengde, Hebei 067000, P.R. China
| | - Fan Li
- Department of Immunology, The Affiliated Hospital of Chengde Medical University, Chengde, Hebei 067000, P.R. China
| | - Qianhui Chen
- Department of Oncology, The Affiliated Hospital of Chengde Medical University, Chengde, Hebei 067000, P.R. China
| | - Yiying Bai
- Department of Oncology, The Affiliated Hospital of Chengde Medical University, Chengde, Hebei 067000, P.R. China
| | - Xinyu Bai
- Department of Oncology, The Affiliated Hospital of Chengde Medical University, Chengde, Hebei 067000, P.R. China
| | - Li Zhang
- Department of Oncology, The Affiliated Hospital of Chengde Medical University, Chengde, Hebei 067000, P.R. China
| | - Lei Liu
- Department of Immunology, The Affiliated Hospital of Chengde Medical University, Chengde, Hebei 067000, P.R. China
| |
Collapse
|
|
2
|
Geng P, Zhao J, Li Q, Wang X, Qin W, Wang T, Shi X, Liu X, Chen J, Qiu H, Xu G. Z-Ligustilide Combined with Cisplatin Reduces PLPP1-Mediated Phospholipid Synthesis to Impair Cisplatin Resistance in Lung Cancer. Int J Mol Sci 2023; 24:17046. [PMID: 38069368 PMCID: PMC10706864 DOI: 10.3390/ijms242317046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2023] [Revised: 11/17/2023] [Accepted: 11/29/2023] [Indexed: 12/18/2023] Open
Abstract
Lung cancer is a malignant tumor with one of the highest morbidity and mortality rates in the world. Approximately 80-85% of lung cancer is diagnosed as non-small lung cancer (NSCLC), and its 5-year survival rate is only 21%. Cisplatin is a commonly used chemotherapy drug for the treatment of NSCLC. Its efficacy is often limited by the development of drug resistance after long-term treatment. Therefore, determining how to overcome cisplatin resistance, enhancing the sensitivity of cancer cells to cisplatin, and developing new therapeutic strategies are urgent clinical problems. Z-ligustilide is the main active ingredient of the Chinese medicine Angelica sinensis, and has anti-tumor activity. In the present study, we investigated the effect of the combination of Z-ligustilide and cisplatin (Z-ligustilide+cisplatin) on the resistance of cisplatin-resistant lung cancer cells and its mechanism of action. We found that Z-ligustilide+cisplatin decreased the cell viability, induced cell cycle arrest, and promoted the cell apoptosis of cisplatin-resistant lung cancer cells. Metabolomics combined with transcriptomics revealed that Z-ligustilide+cisplatin inhibited phospholipid synthesis by upregulating the expression of phospholipid phosphatase 1 (PLPP1). A further study showed that PLPP1 expression was positively correlated with good prognosis, whereas the knockdown of PLPP1 abolished the effects of Z-ligustilide+cisplatin on cell cycle and apoptosis. Specifically, Z-ligustilide+cisplatin inhibited the activation of protein kinase B (AKT) by reducing the levels of phosphatidylinositol 3,4,5-trisphosphate (PIP3). Z-ligustilide+cisplatin induced cell cycle arrest and promoted the cell apoptosis of cisplatin-resistant lung cancer cells by inhibiting PLPP1-mediated phospholipid synthesis. Our findings demonstrate that the combination of Z-Ligustilide and cisplatin is a promising approach to the chemotherapy of malignant tumors that are resistant to cisplatin.
Collapse
Affiliation(s)
- Pengyu Geng
- CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China; (P.G.); (J.Z.); (Q.L.); (X.W.); (W.Q.); (T.W.); (X.S.); (X.L.)
- Liaoning Province Key Laboratory of Metabolomics, Dalian 116023, China
| | - Jinhui Zhao
- CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China; (P.G.); (J.Z.); (Q.L.); (X.W.); (W.Q.); (T.W.); (X.S.); (X.L.)
- Liaoning Province Key Laboratory of Metabolomics, Dalian 116023, China
| | - Qi Li
- CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China; (P.G.); (J.Z.); (Q.L.); (X.W.); (W.Q.); (T.W.); (X.S.); (X.L.)
- Liaoning Province Key Laboratory of Metabolomics, Dalian 116023, China
| | - Xiaolin Wang
- CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China; (P.G.); (J.Z.); (Q.L.); (X.W.); (W.Q.); (T.W.); (X.S.); (X.L.)
- Liaoning Province Key Laboratory of Metabolomics, Dalian 116023, China
| | - Wangshu Qin
- CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China; (P.G.); (J.Z.); (Q.L.); (X.W.); (W.Q.); (T.W.); (X.S.); (X.L.)
- Liaoning Province Key Laboratory of Metabolomics, Dalian 116023, China
| | - Ting Wang
- CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China; (P.G.); (J.Z.); (Q.L.); (X.W.); (W.Q.); (T.W.); (X.S.); (X.L.)
- Liaoning Province Key Laboratory of Metabolomics, Dalian 116023, China
| | - Xianzhe Shi
- CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China; (P.G.); (J.Z.); (Q.L.); (X.W.); (W.Q.); (T.W.); (X.S.); (X.L.)
- Liaoning Province Key Laboratory of Metabolomics, Dalian 116023, China
| | - Xinyu Liu
- CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China; (P.G.); (J.Z.); (Q.L.); (X.W.); (W.Q.); (T.W.); (X.S.); (X.L.)
- Liaoning Province Key Laboratory of Metabolomics, Dalian 116023, China
| | - Jia Chen
- CAS Key Laboratory of Chemistry of Northwestern Plant Resources, Key Laboratory for Natural Medicine of Gansu Province, Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences, Lanzhou 730000, China; (J.C.); (H.Q.)
| | - Hongdeng Qiu
- CAS Key Laboratory of Chemistry of Northwestern Plant Resources, Key Laboratory for Natural Medicine of Gansu Province, Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences, Lanzhou 730000, China; (J.C.); (H.Q.)
| | - Guowang Xu
- CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China; (P.G.); (J.Z.); (Q.L.); (X.W.); (W.Q.); (T.W.); (X.S.); (X.L.)
- Liaoning Province Key Laboratory of Metabolomics, Dalian 116023, China
| |
Collapse
|
|
3
|
Wang Y, Jiang X, Zhang D, Zhao Y, Han X, Zhu L, Ren J, Liu Y, You J, Wang H, Cai H. LncRNA DUXAP8 as a prognostic biomarker for various cancers: A meta-analysis and bioinformatics analysis. Front Genet 2022; 13:907774. [PMID: 36046244 PMCID: PMC9420988 DOI: 10.3389/fgene.2022.907774] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2022] [Accepted: 05/23/2022] [Indexed: 11/13/2022] Open
Abstract
Background: Dual homeoboxes A pseudogene 8 (DUXAP8) is a newly discovered long noncoding RNA that has been shown to function as an oncogene in a variety of human malignant cancers. By integrating available data, this meta-analysis sought to determine the relationship between clinical prognosis and DUXAP8 expression levels in diverse malignancies.Materials and methods: A systematic search was performed to identify eligible studies from several electronic databases from their inception to 25 October 2021. Pooled odds ratios and hazard ratios with 95% CI were used to estimate the association between DUXAP8 expression and survival. For survival analysis, the Kaplan-Meier method and COX analysis were used. Furthermore, we utilized Spearman’s correlation analysis to explore the correlation between DUXAP8 and tumor mutational burden (TMB), microsatellite instability (MSI), the related genes of mismatch repair (MMR), DNA methyltransferases (DNMTs), and immune checkpoint biomarkers.Results: Our findings indicated that overexpression of DUXAP8 was related to poor overall survival (OS) (HR = 1.63, 95% CI, 1.49–1.77, p < 0.001). In addition, elevated DUXAP8 expression was closely related to poor OS in several cancers in the TCGA database. Moreover, DUXAP8 expression has been associated with TMB, MSI, and MMR in a variety of malignancies.Conclusion: This study revealed that DUXAP8 might serve as a prognostic biomarker and potential therapeutic target for cancer. It can be used to improve cancer diagnosis, discover potential treatment targets, and improve prognosis.
Collapse
Affiliation(s)
- Yongfeng Wang
- Graduate School, Ning Xia Medical University, Yinchuan, China
- General Surgery Clinical Medical Center, Gansu Provincial Hospital, Lanzhou, China
- Key Laboratory of Molecular Diagnostics and Precision Medicine for Surgical Oncology in Gansu Province, Gansu Provincial Hospital, Gansu, China
- NHC Key Laboratory of Diagnosis and Therapy of Gastrointestinal Tumor, Gansu Provincial Hospital, Lanzhou, China
- The First Clinical Medical College of Lanzhou University, Lanzhou, China
| | - Xianglai Jiang
- Graduate School, Ning Xia Medical University, Yinchuan, China
- General Surgery Clinical Medical Center, Gansu Provincial Hospital, Lanzhou, China
| | - Dongzhi Zhang
- Graduate School, Ning Xia Medical University, Yinchuan, China
- General Surgery Clinical Medical Center, Gansu Provincial Hospital, Lanzhou, China
| | - Yuanbin Zhao
- The First Clinical Medical College of Lanzhou University, Lanzhou, China
| | - Xiaoyong Han
- Graduate School, Ning Xia Medical University, Yinchuan, China
- General Surgery Clinical Medical Center, Gansu Provincial Hospital, Lanzhou, China
| | - Lihui Zhu
- Graduate School, Ning Xia Medical University, Yinchuan, China
- General Surgery Clinical Medical Center, Gansu Provincial Hospital, Lanzhou, China
| | - Jingyao Ren
- Graduate School, Ning Xia Medical University, Yinchuan, China
- General Surgery Clinical Medical Center, Gansu Provincial Hospital, Lanzhou, China
| | - Yubin Liu
- The First Clinical Medical College of Lanzhou University, Lanzhou, China
| | - Jiarong You
- The First Clinical Medical College of Lanzhou University, Lanzhou, China
| | - Haolan Wang
- General Surgery Clinical Medical Center, Gansu Provincial Hospital, Lanzhou, China
| | - Hui Cai
- General Surgery Clinical Medical Center, Gansu Provincial Hospital, Lanzhou, China
- Key Laboratory of Molecular Diagnostics and Precision Medicine for Surgical Oncology in Gansu Province, Gansu Provincial Hospital, Gansu, China
- NHC Key Laboratory of Diagnosis and Therapy of Gastrointestinal Tumor, Gansu Provincial Hospital, Lanzhou, China
- The First Clinical Medical College of Lanzhou University, Lanzhou, China
- *Correspondence: Hui Cai,
| |
Collapse
|
|
4
|
Creation of Value Chains for the Sustainability of Control and Eradication Actions on Ailanthus altissima (Mill.) Swingle. ENVIRONMENTS 2022. [DOI: 10.3390/environments9050064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Actions to control and eradicate Ailanthus altissima (Mill.) Swingle are essential to the prevention of uncontrolled growth and expansion of this species and its competition with native species. This competition leads to biodiversity and productivity losses in forests. The present study evaluated the potential to create value chains to maintain the sustainability of control actions through the energy recovery of collected A. altissima biomass. Other possibilities were also discussed, such as the extraction of allelopathic compounds. For this purpose, and to assess the potential for energy recovery, samples of A. altissima were collected and analyzed in the laboratory to discuss the potential of using extracted compounds in nature-based applications, and a literature review was carried out. It was found that, although there is potential for the use of these biomasses for energy production, the high levels of chlorine and heavy metals pose some obstacles to their large-scale use, mainly due to their corrosive potential. On the other hand, the extraction of allelopathic compounds was shown to be potentially interesting for use in the control of other invasive species. Used in this application, it may be possible to create value chains to sustain, control, and eradicate the actions of this invasive species.
Collapse
|